CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
智能生物材料提高胶质母细胞瘤免疫治疗效率：最新进展与未来展望
英文原题：Smart biomaterials to enhance the efficiency of immunotherapy in glioblastoma: State of the art and future perspectives.
查看英文原题
Smart biomaterials to enhance the efficiency of immunotherapy in glioblastoma: State of the art and future perspectives.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多形性胶质母细胞瘤（GBM）被认为是中枢神经系统恶性肿瘤中最致命的肿瘤。尽管免疫疗法在癌症治疗中取得了显著进展，但在GBM患者中尚未显示出令人满意的结果。生物材料科学以及纳米生物技术能够优化这些患者中免疫疗法的效率。它们可用于在肿瘤组织中提供免疫细胞的特异性激活以及联合治疗，同时防止由免疫反应过度激活和脱靶效应引起的全身性不良反应。该领域的先进生物材料分为靶向纳米载体和局部递送系统。本综述将概述胶质母细胞瘤的免疫治疗策略以及可能在胶质母细胞瘤治疗中具有高潜力的免疫治疗药物先进递送系统。
展开英文摘要原文
Glioblastoma multiform (GBM) is considered as the most lethal tumor among CNS malignancies. Although immunotherapy has achieved remarkable advances in cancer treatment, it has not shown satisfactory results in GBM patients. Biomaterial science, along with nanobiotechnology, is able to optimize the efficiency of immunotherapy in these patients.
They can be employed to provide the specific activation of immune cells in tumor tissue and combinational therapy as well as preventing systemic adverse effects resulting from hyperactivation of immune responses and off-targeting effect. Advance biomaterials in this field are classified into targeting nanocarriers and localized delivery systems. This review will offer an overview of immunotherapy strategies for glioblastoma and advance delivery systems for immunotherapeutics that may have a high potential in glioblastoma treatment.
论文信息
- 作者
- Abadi B、Yazdanpanah N、Nokhodchi A、Rezaei N
- 第一作者单位
- Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran; Brain Cancer Research Core (BCRC), Universal Scientific Education and Research Network (USERN), Kerman, Iran; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Kerman, Iran.Iran
- 通讯作者单位
- Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: rezaei_nima@tums.ac.ir.Iran
- 文献类型
- 综述
- 期刊
- Advanced drug delivery reviews2021 Dec
- 原文标识
- PubMed 34740765 · DOI 10.1016/j.addr.2021.114035